452 related articles for article (PubMed ID: 18448188)
41. [Surgery for thymomas and thymic carcinomas; treatment results in terms of WHO histologic typing, Masaoka staging system, and p53 expression].
Yamazaki K; Kitada M; Sasaki K; Koshiko S; Hirasawa M; Ozawa K; Kajiura Y; Sasajima T; Miyokawa N
Kyobu Geka; 2002 Oct; 55(11):949-52. PubMed ID: 12391691
[TBL] [Abstract][Full Text] [Related]
42. Tyrosine kinase receptor expression in thymomas.
Henley JD; Cummings OW; Loehrer PJ
J Cancer Res Clin Oncol; 2004 Apr; 130(4):222-4. PubMed ID: 14762710
[TBL] [Abstract][Full Text] [Related]
43. Expression and mutational status of PDGFR in thymic tumours.
Meister M; Kahl P; Muley T; Morresi-Hauf A; Sebening C; Kern MA; Breinig M; Schnabel P; Dienemann H; Schirmacher P; Rieker RJ
Anticancer Res; 2009 Oct; 29(10):4057-61. PubMed ID: 19846951
[TBL] [Abstract][Full Text] [Related]
44. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
45. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
Walts AE; Hiroshima K; Marchevsky AM
Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
[TBL] [Abstract][Full Text] [Related]
46. Expression and mutation analysis of EGFR, c-KIT, and β-catenin in pulmonary blastoma.
Macher-Goeppinger S; Penzel R; Roth W; Dienemann H; Thomas M; Schnabel PA; Schirmacher P; Bläker H
J Clin Pathol; 2011 Apr; 64(4):349-53. PubMed ID: 21292787
[TBL] [Abstract][Full Text] [Related]
47. Expression of neurotrophin receptors in surgically resected thymic epithelial tumors.
Kim DJ; Yang WI; Kim SH; Park IK; Chung KY
Eur J Cardiothorac Surg; 2005 Oct; 28(4):611-6. PubMed ID: 16125946
[TBL] [Abstract][Full Text] [Related]
48. [Correlation between clinical aggressiveness of thymic epithelial tumors and expression of tumor suppressor gene products (p53, p27)].
Fukiwake N; Kase S; Yamazaki K; Yano T; Sugimachi K
Fukuoka Igaku Zasshi; 1999 Aug; 90(8):339-41. PubMed ID: 10496046
[TBL] [Abstract][Full Text] [Related]
49. Receptor tyrosine kinases in sinonasal undifferentiated carcinomas--evaluation for EGFR, c-KIT, and HER2/neu expression.
Chernock RD; Perry A; Pfeifer JD; Holden JA; Lewis JS
Head Neck; 2009 Jul; 31(7):919-27. PubMed ID: 19283847
[TBL] [Abstract][Full Text] [Related]
50. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
51. [Grading of malignancy of thymomas by flow cytometry].
Liu H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Aug; 14(4):310-3. PubMed ID: 1473222
[TBL] [Abstract][Full Text] [Related]
52. Identification of epidermal growth factor receptor (EGFR) exon 20 single nucleotide polymorphism in Chinese squamous cell carcinoma of head and neck (SCCHN).
Jin T; Yu CX; Jin T; Yu CX; Lei DP; Liu DY; Xu FL; Lu YT; Pan XL
Acta Otolaryngol; 2009 Nov; 129(11):1306-12. PubMed ID: 19863329
[TBL] [Abstract][Full Text] [Related]
53. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.
Sato O; Wada T; Kawai A; Yamaguchi U; Makimoto A; Kokai Y; Yamashita T; Chuman H; Beppu Y; Tani Y; Hasegawa T
Cancer; 2005 May; 103(9):1881-90. PubMed ID: 15772959
[TBL] [Abstract][Full Text] [Related]
54. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma.
Biermann K; Göke F; Nettersheim D; Eckert D; Zhou H; Kahl P; Gashaw I; Schorle H; Büttner R
J Pathol; 2007 Nov; 213(3):311-8. PubMed ID: 17768701
[TBL] [Abstract][Full Text] [Related]
55. Absence of gene mutations in KIT-positive carcinoma showing thymus-like elements of the thyroid.
Pan Y; Zhao X; Yang J; Deng J; Zhan Z; Luo Y; Li Q; Guo Y; Zhai Q; Sun B
Hum Pathol; 2012 Mar; 43(3):350-5. PubMed ID: 21835435
[TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor receptor mutations in small cell lung cancer.
Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
[TBL] [Abstract][Full Text] [Related]
57. Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland.
Sung JY; Ahn HK; Kwon JE; Jeong H; Baek CH; Son YI; Ahn YC; Park K; Ahn MJ; Ko YH
J Oral Pathol Med; 2012 May; 41(5):415-23. PubMed ID: 22077630
[TBL] [Abstract][Full Text] [Related]
58. Protein expression and mutational analysis of epidermal growth factor receptor in renal angiomyolipomas.
Lim SD; Kim W; Ahn G; Kwon GY
Pathol Int; 2007 Sep; 57(9):584-8. PubMed ID: 17685929
[TBL] [Abstract][Full Text] [Related]
59. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
Yang B; Chen J; Zhang X; Cao J
Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
[TBL] [Abstract][Full Text] [Related]
60. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
Mitsuhashi T; Nakayama M; Sakurai S; Fujimura M; Shimizu Y; Ban S; Ogawa F; Hirose T; Ishihara O; Shimizu M
Ann Diagn Pathol; 2007 Feb; 11(1):49-54. PubMed ID: 17240308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
